ArticleMethods in molecular biology (Clifton, N.J.)2025
Modified Vaccinia Virus Ankara Titration Using Crystal Violet- or Immuno-Staining in DF-1 Cells.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ibrutinib inhibits the replication of multiple poxviruses by targeting the Bruton tyrosine kinase.Journal of virology · 2025Article
- Vaccinia Virus Vector Bivalent Norovirus Vaccine.Viruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Modified Vaccinia virus Ankara (MVA) is a promising vaccine vector with an outstanding safety profile. The gold standard method to titrate MVA is to immune stain plaques formed in MVA-infected monolayer of primary chicken embryo fibroblasts. Recently, DF-1, an immortal chicken embryo fibroblast line, has also been used. We recently found that MVA plaques in infected DF-1 monolayer could be readily visualized using crystal violet staining, greatly reducing the time and cost of the MVA titration by plaque assay, and with comparable titration results to the gold standard method using immunostaining. Here we present the protocols for MVA amplification and titration using crystal violet- and immuno-staining in DF-1 cells, respectively. Briefly, a fully confluent monolayer of DF-1 cells is infected with MVA at a series of dilutions. The cells are overlaid with media containing methylcellulose, allowing the formation of distinct plaques. After incubating for 2-3 days, the cells are stained with crystal violet or vaccinia virus antiserum, followed by plaque counting.
Indexed as
Identifiers
39621275What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.